whitepaper
Interview: Stefan Braam, CEO & Founder of Ncardia
Mass production with iPSCs: how Ncardia has pushed the boundaries with high-throughput iPSC research.
List view / Grid view
Screening
whitepaper
Whitepaper: Neuroinflammation study
Neuroinflammation study by combining human iPSC-derived astrocytes and HTRF.
whitepaper
Brochure: Particle analysis re-imagined with the Aura™
Get reproducible and quantitative count, size, morphology and particle ID in one system with the Aura™.
whitepaper
Whitepaper: iPSC manufacturing for drug discovery
Controlled manufacturing of hiPSC-derived cardiomyocytes in stirred-tank bioreactors enabling high-throughput phenotypic screening.
news
Novel vitamin K analogue eliminates seizure activity in epileptic mouse models
The vitamin K-based drug has a unique structure which researchers believe makes it effective in controlling even medication-resistant seizures.
news
Novel class of non-addictive analgesics demonstrate safety in animals
To overcome the issues of current analgesics, researchers reveal a new class of non-narcotic pipeline drugs based on acetaminophen.
news
Protective antibodies identified for rare polio-like disease in children
Researchers isolated monoclonal antibodies from children who has survived infection by EV-D68, the virus linked to acute flaccid myelitis (AFM). These antibodies protected mice against infection.
video
Video: Ncardia’s iPSC technology
This Ncardia company presentation will explain how human stem cell technology offers a solution for drug screening as well as cell therapy projects.
news
Novel targeting peptide shows promise against COVID-19 cytokine storm
Experimental peptide combination TAT CARMIL1 reduced collagen degradation as a result of cytokine storm in ex vivo study.
video
On-demand webinar: Protein or not? Advanced high throughput aggregate analysis
Protein Or not? Advanced high throughput aggregate analysis with The Aura™ - Find the problem before it happens particle analysis reimagined.
whitepaper
Application note: Tracking the fate and purge of impurities
Track the emergence and fate of impurities throughout drug development, attach all the relevant analytical data, and store searchable knowledge.
article
Unlocking the power of machine learning for small molecule drug discovery
Rick Wagner of ZebiAI and Patrick Riley of Google Accelerated Science (GAS) discuss the development and benefits of a new machine learning drug discovery platform.
webinar
Drug repurposing approaches to fast track development of new therapies for COVID-19
26 June 2020 | By Tecan
This webinar described the recent efforts to identify small molecule therapeutics for the treatment of SARS-CoV-2 infection and COVID-19 disease.
news
Targeting innate immunity with Transcreener® Assays
Over the past year, BellBrook Labs has leveraged its Transcreener HTS Assay technology to build enabling products and services focusing on innate immunity targets.
news
Promising COVID-19 drug candidate identified by virtual screening
After virtually screening 640 existing drug compounds, researchers have revealed that PC786 potently targets several SARS-CoV-2 receptors, making it a candidate to fight COVID-19.